Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HealthTronics OssaTron

This article was originally published in The Gray Sheet

Executive Summary

Lithotripter premarket approval application submission to FDA covers treatment of plantar fasciitis (heel spurs). The filing had been delayed pending feedback from the agency on clinical trial results (1"The Gray Sheet," Sept. 6, p. 18). The 30-month, multi-site, double-blind study included over 300 patients. The Marietta, Georgia company also is pursuing additional orthopedic applications, including lateral epicondylitis (tennis elbow) and non-union fractures, for which ongoing studies will be expanded in early 2000

You may also be interested in...

HealthTronics OssaTron Lithotripter PMA Submission Planned By Year-End

A premarket approval application for HealthTronics' OssaTron lithotripter for treatment of chronic heel pain due to planar fasciitis should be submitted to FDA by December.

Recent eMDR Change By FDA Asks Adverse Event Reporters About Third-Party Servicers

The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.

Experts: HHS Review Proposal May Free Industry From Regulatory Red Tape

Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts